

DAFTAR PUSTAKA

- Abdelraouf, E. M., Hussein, R. R. S., Shaaban, A. H., El-Sherief, H. A. M., Embaby, A. S., & Abd El-Aleem, S. A. (2022). Annexin A2 (AnxA2) association with the clinicopathological data in different breast cancer subtypes: A possible role for AnxA2 in tumor heterogeneity and cancer progression. *Life Sciences*, 308, 120967.
- Abdollahi, M., Hajizadeh, E., Haghighat, S., & Baghestani, A. R. (2018). *Prognostic Cut Point for Breast Cancer Age of Diagnosis*.
- Adiputra, P. A. T., & Sudarsa, I. W. (n.d.). *Skoring Prognostik Survival Pasien Triple Negative Breast Cancer Berbasis Immunoscore*.
- Ardhiansyah, A. O. (2021). *Dasar-dasar Onkologi dan Hallmark of Cancer (Edisi 2): dari teori preklinik hingga aplikasi klinik* (Vol. 1). Airlangga University Press.
- Arnold, M., Morgan, E., Rungay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., & Siesling, S. (2022). Current and future burden of breast cancer: Global statistics for 2020 and 2040. *The Breast*, 66, 15–23.
- Arzanova, E., & Mayrovitz, H. N. (2022). The Epidemiology of Breast Cancer. *Exon Publications*, 1–19.
- Badowska-Kozakiewicz, A., Budzik, M., Liszcz, A., Sobieraj, M., Czerw, A., Sobol, M., Patera, J., & Deptała, A. (2018). Clinicopathological factors associated with novel prognostic markers for patients with triple negative breast cancer. *Archives of Medical Science*, 15(6), 1433–1442.
- Bai, D., Ueno, L., & Vogt, P. K. (2009). Akt-mediated regulation of NFκB and the essentialness of NFκB for the oncogenicity of PI3K and Akt. *International Journal of Cancer*, 125(12), 2863–2870.
- Bistoni, G., & Farhadi, J. (2015). Anatomy and physiology of the breast. *Plastic and Reconstructive Surgery: Approaches and Techniques*, 477–485.
- Biswas, R. S. R. (2020). Molecular subtypes of breast cancer patients according to St Gallen classification. *Chattagram Maa-O-Shishu Hospital Medical College Journal*, 19(1), 55–58.
- Bland, Kirby I., Helena R. Chang, and Edward M. Copeland III. "Modified radical mastectomy and simple mastectomy." *The breast*. Elsevier, 2018. 443-461.
- Blows, F. M., Driver, K. E., Schmidt, M. K., Broeks, A., Van Leeuwen, F. E.,

- Wesseling, J., Cheang, M. C., Gelmon, K., Nielsen, T. O., & Blomqvist, C. (2010). Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Medicine*, 7(5), e1000279.
- Braicu, C., Chiorean, R., Irimie, A., Chira, S., Tomuleasa, C., Neagoe, E., Paradiso, A., Achimas-Cadariu, P., Lazar, V., & Berindan-Neagoe, I. (2016). Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy. *Expert Reviews in Molecular Medicine*, 18, e18.
- Chaudhary, L. N. (2020). Early stage triple negative breast cancer: management and future directions. *Seminars in Oncology*, 47(4), 201–208.
- Chen, X., He, C., Han, D., Zhou, M., Wang, Q., Tian, J., Li, L., Xu, F., Zhou, E., & Yang, K. (2017). The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. *Future Oncology*, 13(9), 843–857.
- Chen, Jui-Chieh, et al. "The role of the VEGF-C/VEGFRs axis in tumor progression and therapy." *International journal of molecular sciences* 14.1 (2012): 88-107.
- Chiorean, R., Braicu, C., & Berindan-Neagoe, I. (2013). Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? *The Breast*, 22(6), 1026–1033.
- Collignon, J., Lousberg, L., Schroeder, H., & Jerusalem, G. (2016). Triple-negative breast cancer: treatment challenges and solutions. *Breast Cancer: Targets and Therapy*, 93–107.
- Costa, R. E. A. R. da, Oliveira, F. T. R. de, Araújo, A. L. N., & Vieira, S. C. (2021). Prognostic factors in triple-negative breast cancer: a retrospective cohort. *Revista Da Associação Médica Brasileira*, 67, 950–957.
- da Silva, J. L., Nunes, N. C. C., Izetti, P., de Mesquita, G. G., & de Melo, A. C. (2020). Triple negative breast cancer: A thorough review of biomarkers. *Critical Reviews in Oncology/Hematology*, 145, 102855.
- do Nascimento, R. G., & Otoni, K. M. (2020). Histological and molecular classification of breast cancer: what do we know? *Mastology*, 30, 1–8.
- Emdad, L., Das, S. K., Dasgupta, S., Hu, B., Sarkar, D., & Fisher, P. B. (2013). AEG-1/MTDH/LYRIC: signaling pathways, downstream genes, interacting proteins, and regulation of tumor angiogenesis. In *Advances in cancer research* (Vol. 120, pp. 75–111). Elsevier.
- Ensenyat-Mendez, M., Llinàs-Arias, P., Orozco, J. I. J., Íñiguez-Muñoz, S., Salomon, M. P., Sesé, B., DiNome, M. L., & Marzese, D. M. (2021). Current triple-negative breast cancer subtypes: dissecting the most

aggressive form of breast cancer. *Frontiers in Oncology*, 11, 681476.

- Fan, Y., & He, S. (2022). The characteristics of tumor microenvironment in triple negative breast cancer. *Cancer Management and Research*, 1–17.
- Fujii, T., Hirakata, T., Kurozumi, S., Tokuda, S., Nakazawa, Y., Obayashi, S., Yajima, R., Oyama, T. and Shirabe, K., 2020. VEGF-A is associated with the degree of TILs and PD-L1 expression in primary breast cancer. *in vivo*, 34(5), pp.2641-2646.
- Geyer, Felipe C., et al. "The spectrum of triple-negative breast disease: high-and low-grade lesions." *The American journal of pathology* 187.10 (2017): 2139-2151.
- Giuliano, A. E., Edge, S. B., & Hortobagyi, G. N. (2018). of the AJCC cancer staging manual:breast cancer. *Annals of Surgical Oncology*, 25, 1783–1785.
- Gnant, M., Thomssen, C., & Harbeck, N. (2015). St. Gallen/Vienna 2015: a brief summary of the consensus discussion. *Breast Care*, 10(2), 124–130.
- Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., & Bergh, J. (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Annals of Oncology* (9), 2206–2223.
- Hadiyanto, A. V. S., Miranti, I. P., Prajoko, Y. W., & Istiadi, H. (2022). Histological and Clinical Stage Profiles of Young-aged Breast Carcinoma. *Diponegoro International Medical Journal*, 3(1), 1–6.
- Halperin, Edward C., et al. Perez & Brady's principles and practice of radiation oncology. Lippincott Williams & Wilkins, 2013.
- Hamm, C., Kulkarni, S., Gupta, R., Kay, A., Mathews, J., Hirmiz, K., Woldie, I., Ghafoor, A., Elfiki, T., & Kanjeekal, S. (2016). Early Stage triple negative breast cancer has significantly better outcomes than more advanced disease: a single centre retrospective review. *Journal of Cancer Therapy*, 7(10), 665.
- Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. *Cell*, 144(5), 646–674.
- Hashmi, A. A., Hashmi, K. A., Irfan, M., Khan, S. M., Edhi, M. M., Ali, J. P., Hashmi, S. K., Asif, H., Faridi, N., & Khan, A. (2019). Ki67 index in intrinsic breast cancer subtypes and its association with prognostic parameters. *BMC Research Notes*, 12(1), 1–5.
- Hassan, I., Tarcisia, T., Agnestina, A., Cornain, S., & Nasar, I. M. (2013). Ki-67 marker useful for classification of malignant invasive ductal breast cancer. *Universa Medicina*, 32(3), 179–186.

- Hoeferlin, L. A., Chalfant, C. E., & Park, M. A. (2013). Challenges in the treatment of triple negative and HER2-overexpressing breast cancer. *Journal of Surgery and Science*, 1(1), 3.
- Hortobagyi, G. N., Edge, S. B., & Giuliano, A. (2018). New and important changes in the TNM staging system for breast cancer. *American Society of Clinical Oncology Educational Book*, 38, 457–467.
- Houvenaeghel, G., Cohen, M., Classe, J. M., Reyal, F., Mazouni, C., Chopin, N., Martinez, A., Daraï, E., Coutant, C., & Colombo, P. E. (2021). Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study. *ESMO Open*, 6(6), 100316.
- Hu, G., Wei, Y., & Kang, Y. (2009). The multifaceted role of MTDH/AEG-1 in cancer progression. *Clinical Cancer Research*, 15(18), 5615–5620.
- Keam, B., Im, S.-A., Lee, K.-H., Han, S.-W., Oh, D.-Y., Kim, J. H., Lee, S.-H., Han, W., Kim, D.-W., & Kim, T.-Y. (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. *Breast Cancer Research*, 13, 1–7.
- Khan, M., & Sarkar, D. (2021). The scope of astrocyte elevated gene- 1/metadherin (AEG-1/MTDH) in cancer clinicopathology: A review. *Genes*, 12(2), 308.
- Li, C., Li, R., Song, H., Wang, D., Feng, T., Yu, X., Zhao, Y., Liu, J., Yu, X., & Wang, Y. (2011). Significance of aeg-1 expression in correlation with vegf, microvessel density and clinicopathological characteristics in triple-negative breast cancer. *Journal of Surgical Oncology*, 103(2), 184–192.
- Li, J., Yang, L., Song, L., Xiong, H., Wang, L., Yan, X., Yuan, J., Wu, J., & Li, M. (2009). Astrocyte elevated gene-1 is a proliferation promoter in breast cancer via suppressing transcriptional factor FOXO1. *Oncogene*, 28(36), 3188–3196.
- Li, L. T., Jiang, G., Chen, Q., & Zheng, J. N. (2015). Ki67 is a promising molecular target in the diagnosis of cancer. *Molecular Medicine Reports*, 11(3), 1566–1572.
- Liedtke, C., Hess, K. R., Karn, T., Rody, A., Kiesel, L., Hortobagyi, G. N., Pusztai, L., & Gonzalez-Angulo, A. M. (2013). The prognostic impact of age in patients with triple- negative breast cancer. *Breast Cancer Research and Treatment*, 138, 591–599

- Linderholm BK, Hellborg H, Johansson U, Elmberger G, Skoog L, Lehtiö J, Lewensohn R. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. *Ann Oncol*.
- 2009 Oct;20(10):1639-46. doi: 10.1093/annonc/mdp062. Epub 2009 Jun 23. PMID: 19549711..
- Lugano, R., Ramachandran, M., & Dimberg, A. (2020). Tumor angiogenesis: causes, consequences, challenges and opportunities. *Cellular and Molecular Life Sciences*, 77, 1745–1770.
- Łukasiewicz, S., Czezelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. *Cancers*, 13(17), 4287.
- Manna, D., & Sarkar, D. (2021). Multifunctional role of astrocyte elevated gene-1 (AEG-1) in cancer: focus on drug Resistance. *Cancers*, 13(8), 1792.
- Menon, S. S., Guruvayoorappan, C., Sakthivel, K. M., & Rasmi, R. R. (2019). Ki-67 protein as a tumour proliferation marker. *Clinica Chimica Acta*, 491, 39–45.
- Mitas, Michael, et al. "Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene marker panel." *International journal of cancer* 93.2 (2001): 162-171.
- Nurmayeni, N., & Windarti, I. (2022). Gambaran Subtipe Molekuler Kanker Payudara di Indonesia. *Jurnal Agromedicine*, 9(2), 146–149.
- Organization, W. H., Cancer, I. A. for R. on, & Organization, W. H. (2020). *Global cancer observatory*.
- Ostad, S. N., & Parsa, M. (2011). Breast cancer from molecular point of view: Pathogenesis and biomarkers. *Breast Cancer—Focusing Tumor Microenvironment, Stem Cells and Metastasis*.
- Park, S., Park, S., Kim, J., Ahn, S., Park, K. H., & Lee, H. (2018). Assessment of Ki-67 for predicting effective prognosis in breast cancer subtypes. *Biomedical Science Letters*, 24(1), 9–14.
- Pascual, M. C., Montaña, J. J., Franch, P., Sánchez-Contador, C., & Ramos, M. (2022). Survival of Breast Cancer by Stage, Grade and Molecular Groups in Mallorca, Spain. *Journal of Clinical Medicine*, 11(19), 5708.
- Phillips, L., Gill, A. J., & Baxter, R. C. (2019). Novel prognostic markers in triple-negative breast cancer discovered by MALDI-mass spectrometry imaging. *Frontiers in Oncology*, 9, 379.

- Pogoda, K., Niwińska, A., Murawska, M., & Pieńkowski, T. (2013). Analysis of pattern, time and risk factors influencing recurrence in triple-negative breast cancer patients. *Medical Oncology*, 30, 1–8.
- Purwanto, I., Dwiprahasto, I., Aryandono, T., & Mubarika, S. (2020). Treatment options for Indonesian triple negative breast cancer patients: a literature review of current state and potentials for future improvement. *J Med Sci*, 52(1), 81–101.
- Rao, C., Shetty, J., & Prasad, K. H. L. (2013). Immunohistochemical profile and morphology in triple-Negative breast cancers. *Journal of Clinical and Diagnostic Research: JCDR*, 7(7), 1361.
- Reddy, S. M., Sinha, A. K., Hsu, L., Barcenas, C. H., & Valero, V. (2016). *Recurrence and survival outcomes of triple-negative breast cancer survivors disease-free at 5-years and relationship to low hormone receptor positivity (1-9% versus < 1%)*. American Society of Clinical Oncology.
- Santiago, L., Daniels, G., Wang, D., Deng, F.-M., & Lee, P. (2017). Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment. *American Journal of Cancer Research*, 7(6), 1389.
- Shi, X., & Wang, X. (2015). The role of MTDH/AEG-1 in the progression of cancer. *International Journal of Clinical and Experimental Medicine*, 8(4), 4795.
- Simon, Sérgio Daniel, Pedro HZ de Moraes, and Vladimir Galvão de Aguiar. "Adjuvant Chemotherapy of Breast Cancer." *Breast Diseases: An Evidence-Based Pocket Guide* (2019): 489-495.
- Singh, D., Roy, N., & Das, S. M. (2020). Epidemiology, pattern of recurrence and survival in triple-negative breast cancer. *Asian Pacific Journal of Cancer Care*, 5(2), 87–94.
- Sobri, F. B., Azhar, Y., Wibisana, I. G. N., & Rachman, A. (2017). Manajemen terkini kanker payudara. *Media Aesculapius, Jakarta*.
- Sunderkötter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. *J Leukoc Biol*. 1994 Mar;55(3):410-22. doi: 10.1002/jlb.55.3.410. PMID: 7509844.
- Solid, T. W. P. P. K. (2010). *Panduan Penatalaksanaan Kanker Payudara*. PERABOI.
- Song, Z., Chang, Y., Jia, H., Xu, B., Yang, L., Xu, Y., Zhang, J., Wang, M., & Yang, L. (2022). *Metadherin inhibits triple-negative breast cancer chemosensitivity to paclitaxel via activation of the AKT/GSK-3β signaling pathway*.

- Sood, N., & Nigam, J. S. (2014). Correlation of CK5 and EGFR with clinicopathological profile of triple-negative breast cancer. *Pathology Research International*, 2014.
- Sriramulu, S., Sun, X.-F., Malayaperumal, S., Ganesan, H., Zhang, H., Ramachandran, M., Banerjee, A., & Pathak, S. (2021). Emerging role and clinicopathological significance of AEG-1 in different cancer types: a concise review. *Cells*, 10(6), 1497.
- Stuart-Harris, R., Caldas, C., Pinder, S. E., & Pharoah, P. (2008). Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. *The Breast*, 17(4), 323–334.
- Sukumar, J., Gast, K., Quiroga, D., Lustberg, M., & Williams, N. (2021). Triple-negative breast cancer: Promising prognostic biomarkers currently in development. *Expert Review of Anticancer Therapy*, 21(2), 135–148.
- Suyatno, R. K. A., Andinata, B., Iskandar, R. R., & Wibisana, I. G. (2020). Panduan penatalaksanaan kanker. *PERABOI (Perhimpunan Ahli Bedah Onkologi Indonesia)*, 115.
- Swede, H., Sarwar, A., Magge, A., Braithwaite, D., Cook, L. S., Gregorio, D. I., Jones, B. A., R Hoag, J., Gonsalves, L., & L Salner, A. (2016). Mortality risk from comorbidities independent of triple-negative breast cancer status: NCI-SEER-based cohort analysis. *Cancer Causes & Control*, 27, 627–636.
- Tan, H., & Fu, D. (2023). Influence of advanced age on the prognosis of triple-negative breast cancer patients: A surveillance, epidemiology, and end results-based study. *Journal of Cancer Research and Therapeutics*.
- Turkman, Y. E. (2015). Biologic, demographic, and social factors affecting triple negative breast cancer outcomes. *Number 1/February 2015*, 19(1), 62–67.
- Valachis, A., Nyström, P., Fredriksson, I., Wennstig, A.-K., & Ahlgren, J. (2021). Treatment patterns, risk for hospitalization and mortality in older patients with triple negative breast cancer. *Journal of Geriatric Oncology*, 12(2), 212–218.
- Wang, C., & Yang, Q. (2011). Astrocyte elevated gene-1 and breast cancer. *Oncology Letters*, 2(3), 399–405.
- Wang, R.-X., Chen, S., Jin, X., & Shao, Z.-M. (2016). Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. *Scientific Reports*, 6(1), 30091.
- Wang, X.-X., Jiang, Y.-Z., Li, J.-J., Song, C.-G., & Shao, Z.-M. (2016). Effect of nodal status on clinical outcomes of triple-negative breast cancer: a population-based study using the SEER 18 database. *Oncotarget*, 7(29), 46636.

- Widodo, I., Dwianingsih, E. K., Anwar, S. L., Triningsih, F. E., Utoro, T., & Aryandono, T. (2017). Prognostic value of clinicopathological factors for Indonesian breast carcinomas of different molecular subtypes. *Asian Pacific Journal of Cancer Prevention: APJCP*, 18(5), 1251.
- Yavuz, B. B., Aktan, M., & Kanyilmaz, G. (2022). Prognostic Factors in Patients with Triple Negative Breast Cancer Undergoing Adjuvant Radiotherapy: A 10-Year Single Center Experience: Triple negative breast cancer. *Archives of Breast Cancer*, 377–385.
- Yin, J., Zhu, C., Wang, G., & Gu, J. (2022). Treatment for Triple-Negative Breast Cancer: An Umbrella Review of Meta-Analyses. *International Journal of General Medicine*, 5901– 5914.
- Ying, Z., Li, J., & Li, M. (2011). Astrocyte elevated gene 1: biological functions and molecular mechanism in cancer and beyond. *Cell & Bioscience*, 1, 1–6.
- Yoo, B. K., Emdad, L., Lee, S.-G., Su, Z., Santhekadur, P., Chen, D., Gredler, R., Fisher, P. B., & Sarkar, D. (2011). Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiology. *Pharmacology & Therapeutics*, 130(1), 1–8.
- Zuu, GC, Yu CY, She L, Tan HL, Li G, Ren SL, dkk. Regulasi metadherin pada ekspresi faktor pertumbuhan endotel vaskuler bergantung pada jalur p13K/AkT Pada karsinoma sel squamous kepala dan leher. *Obat-obatan*. (2015) 94:502. doi:10.1097/MD.0000000000000502